Evaxion Received A Letter From The Nasdaq Listing Qualifications Department Notifying That It Is Not Currently In Compliance With The Minimum Stockholders' Equity Requirement

5/10/24 5:03:50 PM ET

Biotechnology: Biological Products (No Diagnostic Substances)

Health Care

Get the next $EVAX alert in real time by email

Evaxion Biotech A/S (NASDAQ:EVAX) ("Evaxion" or the "Company"), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, today announced that on May 7, 2024, it received a letter (the "Letter") from the Nasdaq Stock Market LLC ("Nasdaq") Listing Qualifications Department notifying the Company that it is not currently in compliance with the minimum stockholders' equity requirement.

Get the next $EVAX alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$EVAX

Date	Price Target	Rating	Analyst
4/2/2024	$8.00	Neutral → Buy	Ladenburg Thalmann
2/12/2024	$14.00	Buy	H.C. Wainwright

More analyst ratings

$EVAX
Press Releases

Fastest customizable press release news feed in the world

Evaxion receives and appeals delisting determination from Nasdaq, remains committed to Nasdaq listing
As anticipated, Evaxion has received a delisting determinationThe determination has been appealed by Evaxion requesting a hearing on the matter and seeking another 180-day extension to comply with Nasdaq's equity requirementEvaxion remain committed to ensuring compliance and maintain our Nasdaq listing COPENHAGEN, Denmark, November 13, 2024 - Evaxion Biotech A/S (NASDAQ:EVAX) ("Evaxion"), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, has, as anticipated, received a letter dated November 11, 2024, with a delisting determination from Nasdaq Stock Market LLC ("Nasdaq") for failure to maintain stockholders' equity of at least $2.5 million as requir
11/13/24 8:00:00 AM ET
$EVAX
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Evaxion announces positive preclinical data for cytomegalovirus (CMV) vaccine program EVX-V1
New preclinical data demonstrates that CMV antigens identified with Evaxion's AI-Immunology™ platform trigger targeted immune responses Results also showcase the successful design of a proprietary prefusion glycoprotein B (gB) antigen with ability to neutralize the virusEvaxion is advancing these new findings to develop a multi-component CMV vaccine candidateAbout 1 in 200 babies is born with congenital CMV infection and the virus infects approximately 60% to 70% of adults in developed countries. No approved CMV vaccine exists today COPENHAGEN, Denmark, November 12, 2024 - Evaxion Biotech A/S (NASDAQ:EVAX) ("Evaxion"), a clinical-stage TechBio company specializing in developing AI-Immunolog
11/12/24 8:00:00 AM ET
$EVAX
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Evaxion announces business update and third quarter 2024 financial results
COPENHAGEN, Denmark, October 31, 2024 - Evaxion Biotech A/S (NASDAQ:EVAX) ("Evaxion"), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, provides business update and announces third quarter 2024 financial results. Business highlights (since last quarterly update) Since the second quarter 2024 business update, we have continued to execute strongly on our strategy and plans with several major milestones achieved. Key highlights include: Significant expansion of the infectious disease vaccine development collaboration with MSD (tradename of Merck & co., Inc., Rahway, NJ, USA) in a transformative deal for EvaxionContinuously increasing ex
10/31/24 8:00:00 AM ET
$EVAX
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care

$EVAX
Financials

Live finance-specific insights

Evaxion to announce business update and third quarter 2024 financial results on October 31
COPENHAGEN, Denmark, October 28, 2024 - Evaxion Biotech A/S (NASDAQ:EVAX) ("Evaxion"), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, will provide a business update and report its third quarter 2024 financial results on Thursday October 31, 2024, before opening of the Nasdaq CM. Evaxion's Executive Management will host a conference call and webcast the same day at 13:30 CET/08:30 EST, presenting the update and results as well as taking questions. This event is free, open to the public and encouraged. To join the conference call, listen to the presentation and ask verbal questions, please register in advance via this link to receiv
10/28/24 8:00:00 AM ET
$EVAX
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Evaxion to Announce Business Update and Second Quarter 2024 Financial Results on August 14
COPENHAGEN, Denmark, Aug. 12, 2024 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ:EVAX) ("Evaxion" or the "Company"), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, will provide a business update and report its second quarter 2024 financial results on Wednesday, August 14, 2024, before opening of the Nasdaq-CM. Evaxion's Executive Management will host a conference call and webcast the same day at 14:30 CEST/08:30 EDT presenting the update and results as well as taking questions. This event is free, open to the public and encouraged. To join the conference call, listen to the presentation and ask verbal questions, please register in advance v
8/12/24 7:27:00 AM ET
$EVAX
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Fourth quarter and full year 2022 financial results and business update
Evaxion presented promising data from its Phase 1/2a clinical trial of EVX-02 in patients with late-stage melanoma at the 2023 AACR meetingEVX-03, a DNA-based personalized cancer vaccine, is expected to have a CTA filing in Q3 2023 and start a Phase 1 trial in solid tumor patients in Q4 2023Recent collaborations with Pantherna Therapeutics GmbH (utilizing PIONEER™) and ExpreS2ion Biotechnologies ApS (utilizing RAVEN™) highlight the broad utility of Evaxion's differentiated AI platforms, which now includes the new ObsERVTM AI technology, which is designed to identify patient-specific viral targets from endogenous retroviruses (ERVs) known to be overexpressed in certain tumors$13 million in ca
4/27/23 7:00:00 AM ET
$EVAX
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care

Evaxion Received A Letter From The Nasdaq Listing Qualifications Department Notifying That It Is Not Currently In Compliance With The Minimum Stockholders' Equity Requirement

Chat with this insight

Recent Analyst Ratings for
$EVAX

$EVAX
Press Releases

Fastest customizable press release news feed in the world

Evaxion receives and appeals delisting determination from Nasdaq, remains committed to Nasdaq listing

Evaxion announces positive preclinical data for cytomegalovirus (CMV) vaccine program EVX-V1

Evaxion announces business update and third quarter 2024 financial results

$EVAX
Market Insights

Live Market Insights

$EVAX
SEC Filings

Evaxion CEO Christian Kanstrup Reinforces Milestone Timeline And Provides Shareholder Update

Evaxion, On Patent Application for AI-Based Novel Cancer Vaccine Target Identification Method, Says An International Preliminary Report on Patentability Indicates 'promising prospects for obtaining granted patents and protecting the invention'

12 Health Care Stocks Moving In Wednesday's After-Market Session

SEC Form F-1 filed by Evaxion Biotech A/S

SEC Form 6-K filed by Evaxion Biotech A/S

SEC Form 6-K filed by Evaxion Biotech A/S

$EVAX
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

Evaxion Biotech upgraded by Ladenburg Thalmann with a new price target

H.C. Wainwright initiated coverage on Evaxion Biotech with a new price target

Oppenheimer initiated coverage on Evaxion Biotech A/S with a new price target

$EVAX
Large Ownership Changes

This live feed shows all institutional transactions in real time.

SEC Form SC 13G filed by Evaxion Biotech A/S

Amendment: SEC Form SC 13G/A filed by Evaxion Biotech A/S

SEC Form SC 13G filed by Evaxion Biotech A/S

$EVAX
Financials

Live finance-specific insights

Evaxion to announce business update and third quarter 2024 financial results on October 31

Evaxion to Announce Business Update and Second Quarter 2024 Financial Results on August 14

Fourth quarter and full year 2022 financial results and business update

$EVAX
Leadership Updates

Live Leadership Updates

Evaxion Biotech Appoints Dr. Birgitte Rønø as Chief Scientific Officer

Evaxion Biotech Appoints Lars Holtug to the Board of Directors

Evaxion Received A Letter From The Nasdaq Listing Qualifications Department Notifying That It Is Not Currently In Compliance With The Minimum Stockholders' Equity Requirement

Chat with this insight

Recent Analyst Ratings for $EVAX

$EVAX Press Releases

Fastest customizable press release news feed in the world

Evaxion receives and appeals delisting determination from Nasdaq, remains committed to Nasdaq listing

Evaxion announces positive preclinical data for cytomegalovirus (CMV) vaccine program EVX-V1

Evaxion announces business update and third quarter 2024 financial results

$EVAX Market Insights

Live Market Insights

$EVAX SEC Filings

Evaxion CEO Christian Kanstrup Reinforces Milestone Timeline And Provides Shareholder Update

Evaxion, On Patent Application for AI-Based Novel Cancer Vaccine Target Identification Method, Says An International Preliminary Report on Patentability Indicates 'promising prospects for obtaining granted patents and protecting the invention'

12 Health Care Stocks Moving In Wednesday's After-Market Session

SEC Form F-1 filed by Evaxion Biotech A/S

SEC Form 6-K filed by Evaxion Biotech A/S

SEC Form 6-K filed by Evaxion Biotech A/S

$EVAX Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

Evaxion Biotech upgraded by Ladenburg Thalmann with a new price target

H.C. Wainwright initiated coverage on Evaxion Biotech with a new price target

Oppenheimer initiated coverage on Evaxion Biotech A/S with a new price target

$EVAX Large Ownership Changes

This live feed shows all institutional transactions in real time.

SEC Form SC 13G filed by Evaxion Biotech A/S

Amendment: SEC Form SC 13G/A filed by Evaxion Biotech A/S

SEC Form SC 13G filed by Evaxion Biotech A/S

$EVAX Financials

Live finance-specific insights

Evaxion to announce business update and third quarter 2024 financial results on October 31

Evaxion to Announce Business Update and Second Quarter 2024 Financial Results on August 14

Fourth quarter and full year 2022 financial results and business update

$EVAX Leadership Updates

Live Leadership Updates

Evaxion Biotech Appoints Dr. Birgitte Rønø as Chief Scientific Officer

Evaxion Biotech Appoints Lars Holtug to the Board of Directors

Recent Analyst Ratings for
$EVAX

$EVAX
Press Releases

$EVAX
Market Insights

$EVAX
SEC Filings

$EVAX
Analyst Ratings

$EVAX
Large Ownership Changes

$EVAX
Financials

$EVAX
Leadership Updates